Biotech Values

[biotech jim]

Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues

http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2254800

"Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent"

"Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively"

"Patients in Study had History of Heart Attack, Stroke or Symptomatic Peripheral Arterial Disease and Were Treated With Optimized Statin Therapy"


But, there was no difference in cardiovascular death in the Repatha vs control groups, which may be the reason for the AMGN stock drop premarket. May need to see longer followup to see a difference here.